復宏漢霖-B(02696.HK)與Chiome訂立獨家許可協議
格隆匯1月14日丨復宏漢霖-B(02696.HK)公吿，公司已於2021年1月14日與Chiome Bioscience, Inc.（Chiome）訂立獨家許可協議，據此，Chiome同意就針對人體TROP2靶點的抗體及相關的Chiome知識產權向公司授出獨家權利及許可，並於中國（包括香港特別行政區及澳門特別行政區及台灣地區）所有人體疾病治療及診斷應用（放射免疫治療及光免疫治療領域除外）領域內，就許可產品的研究、開發、生產及商業化授出獨家權利。
Chiome將就許可產品授予公司全球範圍（不包括許可區域）的獨家許可權，前提是公司向Chiome發出書面通知以行使被許可方選擇權及公司於行使被許可方選擇權後將於45天內向Chiome支付500萬美元的費用。
倘公司行使其被許可方選擇權，Chiome將獲得許可產品於日本的獨家營銷權（包括再許可權），前提是Chiome將書面通知公司。於行使許可方選擇權後，Chiome將根據Chiome行使其許可方選擇權的時間向公司支付2000萬美元或3500萬美元作為各許可產品的許可首付款。
許可產品是針對人體TROP2靶點的創新單克隆抗體，目前仍處於臨牀前研究階段，具有開發抗體偶聯藥物、雙特異性抗體、與多種抗體聯合治療的潛力。TROP2（滋養層細胞表面抗原2）是一種單次跨膜糖蛋白，在多種實體腫瘤表面高表達，其靶向藥物的潛在適應症包括三陰乳腺癌、非小細胞肺癌及尿路上皮癌等。
Chiome為一家臨牀階段生物科技公司。Chiome成立於2005年，於東京證券交易所創業板上市（代碼：4583），位於日本東京。Chiome聚焦於存在醫療需求缺口的疾病領域（尤其是腫瘤學領域）中抗體療法的發現及開發。Chiome擁有名為ADLib System的自有抗體生成技術，並擁有多項抗體發現、臨牀前及臨牀項目，正就其管線中產品CBA-1205於日本進行首次人體1期研究。
公司表示，許可產品為Chiome研發的創新單克隆抗體，具有開發抗體偶聯藥物、雙特異性抗體、與多種抗體聯合治療多種癌症的潛力。本次合作可利用集團現有的生物創新藥技術及研發平台，進一步豐富產品管線，從而增強集團在腫瘤治療領域的市場競爭力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
